Cancer combination therapy comprising AZD2171 and ZD1839

Details for Australian Patent Application No. 2004255024 (hide)

Owner AstraZeneca AB

Inventors Wedge, Stephen Robert

Agent Davies Collison Cave

Pub. Number AU-B-2004255024

PCT Pub. Number WO2005/004872

Priority 0316127.0 10.07.03 GB

Filing date 8 July 2004

Wipo publication date 20 January 2005

Acceptance publication date 27 September 2007

International Classifications

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61K 41/00 (2006.01) Medicinal preparations obtained by treating materials with wave energy or particle radiation

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

2 February 2006 PCT application entered the National Phase

  PCT publication WO2005/004872 Priority application(s): WO2005/004872

27 September 2007 Application Accepted

  Published as AU-B-2004255024

24 January 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004255026-Dry powder for inhalation comprising a formoterol salt and ciclesonide

2004255023-Combination therapy